Analyst firms · Morgan Stanley · HALO
Morgan Stanley HALO price target and rating history
Halozyme Therapeutics Inc. (HALO) · Health Care
Morgan Stanley rates Halozyme Therapeutics Inc. (HALO) Equal-Weight with a $109 price target, as of its latest action on Nov 11, 2026. It has published 5 rating actions on HALO since September 2022, including 1 upgrade and 2 downgrades. Across 3 firms with a HALO price target in the last 12 months, the median target is $109. Morgan Stanley's target matches it.
- Current rating
- Equal-Weight
- Price target
- $109
- Median target, all firms
- $109
- Actions on HALO
- 5
Morgan Stanley price target on HALO
Every Morgan Stanley rating on HALO
- Nov 11, 2026
- Aug 6, 2025
- May 14, 2025
- Dec 21, 2022
- Sep 9, 2022
How other firms rate HALO
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Morgan Stanley | Equal-Weight | $109 | Nov 11, 2026 |
| Leerink Partners | Outperform | $110 | Aug 7, 2026 |
| Goldman Sachs | Sell | $56 | Dec 4, 2025 |
Questions about Morgan Stanley and HALO
- What is Morgan Stanley's price target for HALO?
- Morgan Stanley's latest stated price target for Halozyme Therapeutics Inc. (HALO) is $109, from its action on Nov 11, 2026.
- What is Morgan Stanley's rating on HALO?
- Morgan Stanley rates HALO Equal-Weight, a neutral rating, as of Nov 11, 2026.
- When did Morgan Stanley last change its view on HALO?
- On Nov 11, 2026, Morgan Stanley downgrades to Equal-Weight from Overweight, price target $109.
- How does Morgan Stanley's HALO target compare with other analysts?
- Across 3 firms with a HALO price target in the last 12 months, the median target is $109. Morgan Stanley's target matches it.
More HALO rating histories
All Morgan Stanley ratingsHALO news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.